FDA approves the first all-oral combination regimen for older adults with newly diagnosed acute myeloid leukemia
Evidence stage: Emerging ClinicalRegulatory status: FDA Approved
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…
Primary source cited
Last reviewed